An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations

A Phase II Randomized Study of Adjuvant Versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma

Observational Study to Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

17-214-09/CA045002:  A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator’s Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell

Decision making and psychological outcomes in low-risk papillary thyroid cancer

A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors

A221405: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy

A021602 – Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus (CABINET)

A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY OF ALT-803, A FUSION PROTEIN ACTIVATOR OF NATURAL KILLER AND T CELLS, IN COMBINATION WITH PEMBROLIZUMAB VS PEMBROLIZUMAB ALONE AS FIRST-LINE TREATMENT FOR PATIENTS

A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High